
# **Aortic Stenosis**


#### **Aortic Stenosis**

Etiology
Physical Examination
Assessing Severity
Natural History
Prognosis
Timing of Surgery

#### Aortic Stenosis: Etiology

- Congenital bicuspid valve is the most common abnormality
- Rheumatic heart disease and degeneration with calcification are found as well










Normal

Bicuspid Ao V "Normal" geriatric Rheumatic calcific valve

#### **Bicuspid Aortic Valve**



#### Aortic Stenosis - Etiology

- Young or middle-aged patient (4 & 5<sup>th</sup> decades) think congenital or rheumatic
  - Bicuspid
    - 2% population
    - 3:1 male:female distribution
    - Co-existing coarctation 6% of patients

Rarely
 Unicuspid valve
 Sub-aortic stenosis

 Discrete
 Diffuse (Tunnel)

 Old patient think degenerative (6,7,8<sup>th</sup> decades)

#### Aortic Stenosis: Symptoms


#### Cardinal Symptoms

- Chest pain (angina)
  - Reduced coronary flow reserve
  - Increased demand-high afterload
- Syncope/Dizziness (exertional pre-syncope)
  - Fixed cardiac output
  - Vasodepressor response
- Dyspnea on exertion & rest
- Impaired exercise tolerance
- Other signs of LV failure
  - Diastolic & systolic dysfunction

# Aortic Stenosis: Physical Findings

- Intensity DOES NOT predict severity
- Presence of thrill DOES NOT predict severity
- "Diamond" shaped, harsh, systolic crescendo-decrescendo
- Decreased, delay & prolongation of pulse amplitude
- Decreasing intensity of S2
- S4 (with left ventricular hypertrophy)
- S3 (with left ventricular failure)

# Aortic Stenosis: Physical Findings




#### Severity of Stenosis


Normal aortic valve area 2.5-3.5 cm<sup>2</sup> Mild stenosis 1.5-2.5 cm<sup>2</sup> Moderate stenosis 1.0-1.5 cm<sup>2</sup> Severe stenosis  $< 1.0 \text{ cm}^2$ Critical stenosis < 0.7 cm<sup>2</sup> Onset of symptoms  $\sim 0.9 \text{ cm}^2$  with CAD  $\sim 0.7 \text{ cm}^2$  without CAD

#### Diagnosis: Echocardiogram


- Etiology
- Valve gradient and area
- LVH
- Systolic LV functionDiastolic LV function
- LA size
- Concomitant regional wall motion abnormalities
- Coarctation associated with bicuspid AV



# Echocardiogram




#### **Doppler estimation of AVA**



#### Cardiac catheteriztion

#### Gorlin Method




Simplified: Hakke's formula  $AVA=CO/\sqrt{(p-p gradient)}$ 

#### Low gradient AS

Calculated AVA is < 1.0 cm<sup>2</sup>, But... AV gradient is <30mmHg. Stenotic or not Stenotic?

#### Low gradient AS




#### Aortic Stenosis: Prognosis


Live			
expectancy			
5 years			
2-3 years			
1-2 years			

Therapy: Valve replacement for severe aortic stenosis Operative mortality (elderly) ~ 4%/Morbidity ~ 3-11% Event rate in asymptomatic severe AS ~ 1%/year

### Natural History of Aortic Stenosis

Heart failure reduces life expectancy to less than 2 years Angina and syncope reduce life expectancy between 2 and 5 years Rate of progression ↓ @ 0.1 cm2/year





# Operative mortality of AVR in the elderly

- ~ 4-24%/year
- Risk factors for operative mortality
  - Functional class
  - Lack of sinus rhythm
  - HTN
  - Pre-existing LV dysfunction


- Aortic regurgitation
- Concomitant surgical procedures:CABG/M
  - V surgery
- Previous bypass
- Emergency surgery
- CAD
- Female gender

# AVR is recommended in symptomatic patients with severe AS (stage D1) with :

Decreased systolic opening of a calcified or congenitally stenotic aortic valve; and An aortic velocity 4.0 m per second or greater or mean pressure gradient 40 mm Hg or higher; and Symptoms of HF, syncope, exertional dyspnea, angina, or (pre)syncope by history or on exercise testing.

#### **PARTNER Study Design**

#### Symptomatic Severe Aortic Stenosis




• Primary endpoint evaluated when all patients reached one year follow-up.

• After primary endpoint analysis reached, patients were allowed to cross-over to TAVR.

#### All-Cause Mortality Landmark Analysis

					+ $+$		d Rx (n =	179)	
	CI] = 0.50 [0.3 og rank) < 0.00					TAVR (n =	= 179)		
		HF	0.46 [0.32, 0.6 k) < 0.0001	66]		Cl] = 0.47 [0 og rank) = 0.			
lity (%)	0.4		0			0.5		66.7%	
All-Cause Mortality (%)	0-1 Year	50.8%	-3 ars		61.1%	3-5 Years	5		
All-Caus		30.7%		3	3.4%			38.9%	
		12	24 3 Mon			48			



#### **Prosthetic Heart Valves**

### Caged-Ball Valve



#### **Bio-prosthetic Valve**

#### **Prosthetic Valves**

#### MECHANICAL

- Durable
- Large orifice
- High thromboembolic
   potential
- Best in Left Side
- Chronic warfarin therapy

#### BIO-PROSTHETIC

- Not durable
- Smaller orifice/functional stenosis
- Low thromboembolic potential
- Consider in elderly
- Best in tricuspid position

